摘要
目的探讨Ⅱ期非小细胞肺癌(NSCLC)中Stathmin mRNA和蛋白表达水平与患者预后的关系。方法单基因定量法检测已手术Ⅱ期NSCL-C患者肿瘤组织中Stathmin mRNA表达;免疫组化法检测患者肿瘤组织中Stathmin蛋白表达水平。所有患者行长春瑞滨联合顺铂方案化疗,统计学分析其表达水平与患者临床病理学特征之间的关系,并随访患者的无瘤生存时间(DFS)和总体生存时间(OS),统计学分析StathminmRNA和蛋白表达水平与患者的DFS、OS的关系。结果Stathmin mRNA表达水平与患者的T、N分期显著相关,与患者的年龄,病理类型均无显著相关性;Stathmin蛋白表达水平与患者的年龄、病理类型、T、N分期均无显著相关性;Stathmin mRNA和蛋白表达水平与患者的OS,DFS均无显著相关性。结论Ⅱ期NSCLC患者肿瘤组织中Stathmin表达水平不能作为预测患者预后的指标。
Objective To investigate the expression of Stathmin in stageⅡ non- smal celllung cancer （NSCLC） and its significance. Methods The expression of Stathmin mRNA and protein was detected by Quanti- Gene Assay and immunohisto-chemistry, respectively. Al patients received NP chemotherapy. The patients were fol owed- up;the disease- free survival （DFS） and overal survival （OS） were observed. The correlation of Stathmin expression level with the clinicopathological features of NSCLC and prognosis of patients were analyzed. Results Stathmin mRNA expression levels was significantly correlated with T stage and N stage. There was no significant correlation of Stathmin mRNA and protein expression levels with the OS and DFS of patients. Conclusion In patients with stage Ⅱ NSCLC, the expression levels of Stathmin mRNA and protein in cancer tissue cannot be used as a prognostic indicator.
出处
《浙江医学》
CAS
2014年第4期255-258,共4页
Zhejiang Medical Journal
基金
浙江省教育厅资助课题(2007-01345)
